KNOW Bio – Vast Therapeutics Announces BIOC11 testing results for Nontuberculous Mycobacteria (NTM) in Animal Model

Vast’s Second Drug Candidate achieves 99% reduction of NTM

DURHAM, NC – October 22, 2019 – Vast Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, announces that BIOC11 eradicated 99% of the Nontuberculous Mycobacteria (NTM) in an in vivo animal model of infection; this data will be presented at the National Cystic Fibrosis Conference to be held in Nashville, Tennessee from October 31 to November 2, 2019.